Skip to content
We need to make progress against the next pandemic, Phyllis Arthur, Senior Vice President of Infectious Diseases & Emerging Science Policy at the Biotechnology […]
Plan now for next pandemic, BIO’s Phyllis Arthur tells UN preparedness panel Read More »
On September 20, the House Energy & Commerce Oversight and Investigations Subcommittee will explore how the drug price controls in the Inflation Reduction Act
BIO Vice Chair John F. Crowley to testify on Inflation Reduction Act price controls Read More »
Between the buzzing and the painful stings, one might argue that bees can be annoying. But to put it simply: if bees go extinct,
Can biotech save the bees? Read More »
Lawmakers introduced the Optimizing Research Progress Hope and New Cures (ORPHAN Cures Act) on September 18, a bill the Biotechnology Innovation Organization (BIO) said
ORPHAN Cures Act introduced to boost new rare disease drug development Read More »
Within the challenging field of protein misfolding research, there is a company with a unique and competitive edge that is turning heads and making
BIO’s Emerging Start-Up Stadium winner: Paradox Immunotherapeutics Read More »
Out of the University of Miami, the industry’s first investigator-initiated emergency trial treating a pregnant mother has been authorized by the U.S. Food and
BIO’s Seed-Stage Start-Up Stadium winner: PriZm Therapeutics Read More »
The BIO Investor Forum 2023, hosted by the Biotechnology Innovation Organization (BIO), is right around the corner. Returning to San Francisco on October 17-18,
Why attend the BIO Investor Forum 2023? An investor and a company explain. Read More »
The Inflation Reduction Act (IRA) includes a misguided plan to control prices that will only result in costlier medicine and reduced access, lawmakers and
Why drug price controls ‘risk the future of investment’ in R&D Read More »
September 15 marks the start of Hispanic Heritage Month, an annual reminder and chance to honor the countless contributions made by members of the
Kathleen Coviello is the New Jersey Economic Development Authority’s (NJEDA’s) Chief Economic Transformation Officer. In this role, she oversees the authority’s strategic sector, economic
New Jersey: a state for life sciences businesses of all sizes Read More »
